Clin Cancer Res. 2023 Oct 4. doi: 10.1158/1078-0432.CCR-23-1340. Online ahead of print.
ABSTRACT
Since the first approval of a tumor-agnostic indication in 2017, a total of seven tumor-agnostic indications involving six drugs have received approval from the US Food and Drug Administration. In this paper, the master protocol subteam of the Statistical Methods in Oncology Scientific Working Group, Biopharmaceutical Session, American Statistical Association, provides a comprehensive summary of these seven tumor-agnostic approvals, describing their mechanisms of action; biomarker prevalence; study design; companion diagnostics; regulatory aspects, including comparisons of global regulatory requirements; and Health Technology Assessment approval. Also discussed are practical considerations relating to the regulatory approval of tumor-agnostic indications, specifically: (1) recommendations for the design stage to mitigate the risk that exceptions may occur if a treatment is initially hypothesized to be effective for all tumor types; and (2) because drug development continues after approval of a tumor-agnostic indication, recommendations for further development of tumor-specific indications in frontline patients in the setting of a randomized confirmatory basket trial, acknowledging the challenges in this area. These recommendations and practical considerations may provide insights for the future development of drugs for tumor-agnostic indications.
PMID:37792436 | DOI:10.1158/1078-0432.CCR-23-1340
